Conditions: Attention Deficit Hyperactivity Disorder ADHD
Keywords: Attention Deficit Hyperactivity Disorder Stimulant Non-stimulant Drug Methylphenidate Atomoxetine Strattera Concerta MACRO Medication Treatment Youth Adolescent Functional Magnetic Resonance Imaging Brain scan Imaging Response inhibition Inattentive Hyperactive Combined Medication Treatment Brain Imaging
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 127
Healthy volunteers: yes

Brief summary:
The growing number of medications used to treat attention-deficit/hyperactivity disorder (ADHD) raises important questions about whether different medications have similar or different therapeutic mechanisms of action. We have recently shown that the stimulant methylphenidate (MPH) and the non-stimulant atomoxetine (ATX) produce clinical improvement via a common mechanism in motor cortex, and distinct actions in frontostriatal and midline cingulate-precuneus regions. These exciting findings offer a window into the common and unique neurophysiological mechanisms of response to stimulant and non-stimulant treatments. However, the interpretation and clinical utility of these results would be greatly enhanced by in-depth investigation of the impact of the two treatments on relevant neural networks, and analyses which evaluate whether improvement is achieved via normalization or other adaptive changes in brain function.

Detailed description:
The specific aims of this project are to use functional magnetic resonance imaging (fMRI) to determine the significance of activation changes over treatment related to clinical improvement, and the impact of treatment on neural connectivity within and between the anti-correlated frontostriatal 'task-positive' circuit and cingulate-precuneus 'task-negative' network. Our central hypotheses are that clinical improvement is associated with: (i) normalization of reduced connectivity of regions within the 'task-positive' network, with resultant increased inhibition of motor cortex, and (ii) normalization of low task-related connectivity in regions within the task-negative network for MPH and the 'task-positive' network for ATX.

This research proposes to test a model which posits a neurophysiological basis of mechanisms of response to stimulant and non-stimulant medications, and fits with our long term objectives of being able to match treatments to individual patients. Testing this model requires large samples of youth scanned using fMRI before and after treatment, and matched healthy controls also scanned twice. We will use an innovative network-based approach to study the effects of treatment, building on results from our current fMRI treatment study, and incorporating new theoretical approaches to understanding ADHD and its treatment.

Arms:
arm 1: Healthy Control Group: will receive initial evaluation, and 2 fMRI (functional magnetic resonance imaging) scans each 6-8 weeks apart arm 2: These subjects will receive initial evaluation and baseline fMRI scan, flexible dose titration with atomoxetine for 6-8 weeks, and fMRI postscan, with optional post study stabilization visits. arm 3: Subjects will receive initial evaluation, baseline fMRI scan, flexible dose titration with methylphenidate (Concerta) for 6-8 weeks, and fMRI scan post treatment.

Interventions: intervention 1: fMRI scans intervention 2: Atomoxetine arm intervention 3: Methylphenidate arm
Intervention descriptions: intervention 1: 2 fMRI scans 6-8 weeks apart intervention 2: Flexible dose titration with atomoxetine prescribed at weekly visits for 6-8 weeks intervention 3: Flexible dose titration with methylphenidate for 6-8 weeks, with optional post study stabilization visits.

Protocol document:
Prot_000.pdf: 
 
Imaging Stimulant and Non-Stimulant Treatments for ADHD: A Network-Based 
Approach  
PI: Jeffrey Newcorn 
NCT01678209 
Document Date: 5-6-2019


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
2 
Revised  9/2/14 
MSSM Protocol Template HRP-503a 
Brief Summary of Research (250-400 words): 
The growing number of medications used to treat attention-deficit/hyperactivity disorder 
(ADHD) raises important questions about whether different medications have similar or 
different therapeutic mechanisms of action. We have recently shown that the stimulant 
methylphenidate (MPH) and the non-stimulant atomoxetine (ATX) produce clinical 
improvement via a common mechanism in motor cortex, and distinct actions in 
frontostriatal and midline cingulate-precuneus regions. These exciting findings offer a 
window into the common and unique neurophysiological mechanisms of response to 
stimulant and non-stimulant treatments. However, the interpretation and clinical utility of 
these results would be greatly enhanced by in-depth investigation of the impact of the 
two treatments on relevant neural networks, and analyses which evaluate whether 
improvement is achieved via normalization or other adaptive changes in brain function. 
In addition, it would be useful to examine the relationship between a variety of 
demographic and clinical characteristics (e.g., age, sex, adhd symptom severity, etc) 
and fMRI profiles pre-treatment. Assessing this question requires a relatively larger data 
set. Which can best be achieved by combining the data from the various studies 
indicated. 
 
1) Objectives: 
Research Question: 
The specific aims of this project are to use functional magnetic resonance imaging 
(fMRI) to determine the significance of activation changes over treatment related to 
clinical improvement, and the impact of treatment on neural connectivity within and 
between the anti-correlated frontostriatal ‘task-positive’ circuit and cingulate-precuneus 
‘task-negative’ network. Our central hypotheses are that clinical improvement is 
associated with: (i) normalization of reduced connectivity of regions within the ‘task-
positive’ network, with resultant increased inhibition of motor cortex, and (ii) 
normalization of low task-related connectivity in regions within the task-negative network 
for MPH and the ‘task-positive’ network for ATX. 
 
This research proposes to test a model which posits a neurophysiological basis of 
mechanisms of response to stimulant and non-stimulant medications, and fits with our 
long term objectives of being able to match treatments to individual patients. Testing 
this model requires large samples of youth scanned using fMRI before and after 
treatment, and matched healthy controls also scanned twice. We will use an innovative 
network-based approach to study the effects of treatment, building on results from our 
current fMRI treatment study, and incorporating new theoretical approaches to 
understanding ADHD and its treatment. 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
3 
Revised  9/2/14 
In addition we now wish to examine the relationship between a variety of demographic 
and clinical characteristics (e.g., age, sex, adhd symptom severity, etc) and fMRI profiles 
pre-treatment. 
 
2) Background 
The increasing number of medications used to treat ADHD in children raises important 
questions about the mechanisms by which these different classes of compounds exert 
their therapeutic effects. This project will establish the therapeutic mechanisms of action 
of the stimulant methylphenidate and non-stimulant atomoxetine, by answering two key 
questions: 1) to what extent do effective treatments result in “normalization” of aberrant 
brain pathophysiology and/or new “adaptive” or compensatory changes in 
neurophysiology - focusing on the interactions between neural networks implicated in 
ADHD; and 2) what are the common and unique mechanisms of action of the two 
medications on ‘task-positive’ and ‘task-negative’ neural networks? 
 
In addition, there are few studies which have used fMRI to examine the relationship 
between a variety of demographic and clinical characteristics (e.g., age, sex, adhd 
symptom severity, etc) and fMRI profiles pre-treatment. 
 
3) Setting of the Human Research 
Participants will be consented and evaluated at Mount Sinai in the department of 
Child and Adolescent Psychiatry in the 19 East 98th Street building, 5th floor- 
Room 5E. The fMRI scans will be conducted in the Radiology department, 
Translational and Molecular Imaging Institute (TMII).  
Participants are only recruited through the existing protocols and no additional 
participants will be recruited and consented for the combined data set without 
prior approval from the PPHS.  
 
4) Resources Available to Conduct the Human Research 
Beth Krone, PhD and Jeffrey Newcorn, MD, will follow all subjects in the study, 
along with supervised medical trainees from the Icahn School of Medicine, who 
are to be determined.  Study coordinators and research assistants will assist in 
following subjects and fMRI scanning. Staff from clinics and practices within the 
Mount Sinai Health System will assist with patient referrals.  Kurt Schulz, PhD will 
supervise all fMRI scanning and scan data collection.  
Beth Krone has worked in Dr. Newcorn’s lab since 2008. Dr. Krone is a clinical 
psychologist with extensive prior experience in clinical research, cognitive and 
neuopsychological assessments, and group and individual counseling. She 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
4 
Revised  9/2/14 
completed her certificates for Human Research Protection, HIPPA, and 
Research Data Security, as well as “Basic IRB Training for Clinical Research 
Coordinators” and CITI-training modules for Mount Sinai.  
In addition to personnel and facilities that are being used to continue the activities 
performed under the NIH grant R01MH095766, the research team has access to 
existing, de-identified datasets that contain baseline clinical, behavioral, and fMRI 
data from children and adolescents ages 7 to 17 years old who participated in 
Investigator Initiated trials (GCOs 02-0243, 03-1169, 04-0059, and 09-1825). The 
investigators will use this baseline data to augment the sample size, and 
increase power of the analyses. 
Note that no clinical assessments will be conducted outside of these protocols for 
inclusion as part of the combined data set that will be used for additional 
analyses that were approved on 9/19/16 by the PPHS. We will simply be 
examining aggregate de-identified data across studies for these additional 
analyses. 
5) Study Design 
a) Recruitment Methods 
Youth will be recruited for the treatment study using multiple methods to ensure 
representativeness:  
 
ResearchMatch will be used as a method for identifying and contacting 
potential subjects.  The study specific announcement is included with this 
submission.  
 
We will publicize the study to colleagues at our institution throughout the 
Mount Sinai Health system, including our research partners and clinical 
programs 
 
We will contact past participants of GCO 03-0612, 09-1825, and 10-0435 
studies who indicated on their consent forms that they would like to be 
contacted regarding future studies. 
 
Dr. Halperin, Co-I on this study, has been conducting an NIH-funded 
longitudinal study of preschool children who were deemed to be either at risk 
for ADHD or typically developing when they were 3-4 years-old (R01 
MH068286-08) for the past 8 years at Queens College/CUNY. Currently, the 
majority of these children are between the ages of 8 and 11 years-old, and 
approximately 75 of them met diagnostic criteria for ADHD at their last 
evaluation. Although diagnosed with ADHD, these children do not receive 
treatment from his study, although it would likely be advantageous for many 
of them. As such, this sample may serve as a source of referrals for this 
study at Mount Sinai. The IRB at Queens College allows Dr. Halperin to post 
fliers for other related research studies on the bulletin board in his waiting 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
5 
Revised  9/2/14 
room, and in the past, his study parents have participated in several of these 
posted studies. 
 
We will advertise in the electronic (e.g., Craig’s List) and news media, and 
post the study on relevant web sites (e.g., Center Watch; CHADD, AACAP, 
etc.).  
 
We will make information about the study known to the potential target 
audience by mailings from the local chapter of CHADD, mailings to clinic 
directors, as well as mailings to local pediatric and psychiatric practitioners. 
 
We will include information about study recruitment in lectures given in 
academic and community settings, and through a series of educational and 
outreach efforts to be conducted in our local communities.   
 
Study coordinators will also contact school psychologists at private and 
parochial schools for potential referrals. 
 
Word of mouth   
All advertisements and letters used for recruitment will be submitted to the IRB for 
approval and a script for recruitment in the Outpatient Clinic has been included with 
the application packet. The script provided to the clinic contains other referral options 
both within and outside Mount Sinai. The study is not represented as the patient’s 
only potential option for care.  
School psychologists will be provided with material from the Mount Sinai ADHD 
Center, the outpatient clinic, and IRB approved materials that discuss the research 
program. The school psychologist may choose to distribute the information to 
parents and guardians. We offer materials for counselors to offer parents during their 
routine feedback sessions, AND WILL MAKE IT CLEAR THAT RESEARCH IS AN 
OPTION. This does not introduce any additional risk to the common practice of 
teachers’ routine identification of children in need of intervention in their classrooms. 
Each school will have its own procedures for how the teachers and counselors 
proceed with offering recommendations and resources to parents of these children. 
The site will respond to telephone and email inquiries from any school personnel; 
however, the site will never contact potential participants based on these referrals 
without their prior knowledge. Either the referral clinician will ask the participant to 
call the site or the referral source will seek approval from the parent prior to a request 
for the site to call. 
When initial contact is made, the participant’s eligibility will be assessed using a 
questionnaire/screener. Our current pre-screening form was designed in 
collaboration with, and approved by, our PPHS to meet  their criteria precluding 
requirement of consent. With it, we inform the parent about specific 
inclusion/exclusion criteria and the symptoms of ADHD, ask the parent’s opinion 
about whether the child meets these criteria, and obtain the identifying information 
necessary for scheduling appointments that are required for screening (CRC nursing 
and mock scanning). To meet PPHS criteria to preclude consent, we: 1) record all 
identifying information on a page separate from the remainder of the document, so 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
6 
Revised  9/2/14 
that it can be dissociated from any response notes about the inclusion/exclusion 
criteria. Thus, any notes about whether the parent feels the child can swallow pills, 
will agree to urine testing, or has symptoms of ADHD, etc., are not identifiable; and 
2) We place a notice on the forms to instruct staff to refrain from using for research 
any of the de-identified notes, or the identifying information necessary for 
administrative purposes. This reads as: ‘This form is not to be used as research 
data!’ The pre-screening form is essential for educating potential participants about 
the study inclusion and exclusion criteria, reducing the number of children who go 
through a rigorous screening process when they are clearly not going to meet 
inclusion/exclusion criteria, and collecting the administrative information required by 
CRC and the TMII. It is not a research tool, and it is not used as information during 
the actual screening. Identifying information regarding the participant will not be 
recorded on the screen if potential eligibility is unlikely and/or the participant has no 
further interest in the study or future studies. We will unlink the pre-screening 
information from the identifying information. Only an IRB-approved screen will be 
used. A copy has been provided with the submission packet. 
 
No new recruitment will be done for the assessments done in the combined data set.  
 
b) Inclusion and Exclusion Criteria 
General inclusion criteria for subjects with ADHD and healthy controls are:  
 aged 7-17 years;  
 Wechsler Intelligence Scale for Children (WISC) scores ≥ 75;  
 informed consent and assent to study participation.  
 
General exclusion criteria are:  
 history of head injury with loss of consciousness or any CNS disease that is 
likely to affect brain function;  
 diagnosis of autism or pervasive developmental, psychotic, major mood, and 
Tourette’s disorder;  
 alcohol or drug abuse in the past 3 months or a positive urinary toxic screen 
on initial evaluation;  
 use of psychotropic medication within 2 weeks of the study (8 weeks for 
fluoxetine);  
 pre-existing medical or psychological condition which precludes being in the 
scanner (e.g., claustrophobia, morbid obesity);  
 metal in the body that cannot be removed (e.g., braces, metal plate);  
 positive urine pregnancy test. 
 
Specific inclusion criteria for youth with ADHD are:  


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
7 
Revised  9/2/14 
 
diagnosis of ADHD, any subtype, determined by Kiddie Schedule for Affective 
Disorders and Schizophrenia for School-Aged Children-Present and Lifetime 
Versions (K-SADS-PL);  
 
ADHD Rating Scale-IV-Parent Version: Investigator Administered (ADHD-
RSIV) total score ≥ 1.5 SD above age and gender means for subtype 
 
Clinical Global Impressions–ADHD–Severity (CGI-S) score ≥ 4;  
 
ADHD must be the primary diagnosis and focus of treatment, and the 
treatments offered in the study must not be contraindicated for the comorbid 
disorder.  
 
Specific exclusion criteria for the treatment trial include:  
 
previous unsuccessful trial of MPH or ATX that was adequately dosed (≥ 1 
mg/kg for MPH or 1.0 mg/kg for ATX) and of adequate duration (≥ 4 weeks);  
 
abnormal findings on physical exam, or vital signs 
 
pulse and blood pressure > 95% of age and gender mean;  
 
inability to swallow capsules;  
 
weight is < 20 kg or > 85 kg.  
 
Specific inclusion/exclusion criteria for control youth include:  
 
no past history or current diagnosis of any psychiatric disorder, determined by 
the K-SADS-PL interview ADHD-RS-IV and CBCL scores for each symptom 
domain ≤ 1 SD of age and gender means. 
c) Number of Subjects 
In the current study, eighty subjects with ADHD will be enrolled for assessment; of these 
we expect 60 to qualify for the pre-treatment fMRI scan. Only those who are successfully 
scanned (approximately 52) will be randomized to treatment. It is expected that 40 of 
these will complete the full clinical trial and the post-treatment fMRI scan. 
 
Sixty four sex, age- and gender-matched healthy control subjects will also be enrolled for 
assessment. It is expected that 56 will qualify as healthy controls, 48 will be able to 
complete the baseline fMRI scan, and 40 will return for repeat scanning and complete 
the time 2 scan 
 
In addition to these participants, the combined data set will include deidentified data from 
the above named studies. 
 
d) Study Timelines 
First Patient, First Visit:   September, 2012   
 
Last Patient, First Visit: 
September, 2017  
 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
8 
Revised  9/2/14 
Last Patient, Last Visit: 
November, 2017  
 
Completed Manuscript: 
July, 2019 
e) Study Endpoints 
Baseline and End-of-Study assessment measures:  
 
Clinical Global Impressions-Severity (CGI-S) 
 
Child Behavior Checklist (CBCL) 
 
Wechsler Intelligence Scale for Children–Fourth Edition (WISC-IV) 
 
Attention Networks Test (ANT) 
 
Continuous Performance Test (CPT) 
 
Finger Windows 
 
Digit Span 
 
Columbia Suicide Severity Rating Scale (CSSRS) 
 
Atomoxetine-Stimulant Side Effects Rating Scale (ASSERS)  
 
fMRI procedures with go-nogo task, diffusion tensor imaging (DTI) and 
resting state 
 
Conners’ Parent Rating Scales Revised- Short Version (CPRS R:S) and 
Conner’s Teacher Rating Scales Revised – Short Version (CTRS R:S) 
questionnaires (baseline only) 
 
Weiss Functional Impairment Rating Scale Parent-Report (WFIRS-P) 
questionnaire 
 
ECG as considered necessary at screening by Dr. Newcorn 
 
f) Procedures Involved in the Human Research 
Procedures for research include routine medication visits (reporting of related and 
non-related symptoms, evaluation of medication tolerance, dispensing of study 
medication and collection of empty study medication packages for drug 
accountability procedures) participant interviews, questionnaires and fMRI scans.   
 
 
Informed Consent/HIPPA NOPP  
 
Hollingshead Index for socioeconomic status 
 
Collection of Patient Demographics  
 
Mock Scan  
 
Kiddie SADS-Present and Lifetime Versions (K-SADS-PL)  
 
Clinical Global Impressions - Severity (CGI-S)  
 
Clinical Global Impressions - Improvement (CGI-I)  
 
Child Behavior Checklist (CBCL)  
 
Wechsler Intelligence Scale for Children–Fourth Edition (WISC-IV)  
 
Wechsler Individual Achievement Test–Second Edition (WIAT-II)  
 
ADHD Rating Scale-IV-Parent-Investigator Version (ADHD-RS-IV)  


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
9 
Revised  9/2/14 
 
Atomoxetine – Stimulant Side Effect Rating Scale (ASSERS)  
 
Columbia Suicide Severity Rating Scale (C-SSRS)  
 
Social Skills Rating System (SSRS) questionnaire – parent version 
 
Weiss Functional Impairment Rating Scale Parent-Report (WFIRS-P) 
questionnaire 
 
Conners’ Parent Rating Scales Revised- Short Version (CPRS R:S) and 
Conner’s Teacher Rating Scales Revised – Short Version (CTRS R:S) 
questionnaires 
 
Handedness Questionnaire (adapted from the Edinburgh inventory, Oldfield 
1971) 
 
Blood for Genetics analyses 
 
Finger Windows Test  
 
Attention Network Test (ANT)  
 
Continuous Performance Test (CPT) 
 
Digit Span Test  
 
Vital Signs: Height, Weight, Pulse, BP, Temp  
 
Urine Pregnancy Test (post menarchcal females only) 
 
Urine Toxicology  
 
Physical Exam  
 
Concomitant medications  
 
fMRI procedures with Go/No-Go task, diffusion tensor imaging (DTI) and 
resting state 
 
ECG or additional examinations as indicated for clinical clearance in cases 
with past or family history  
 
Results of pregnancy and drug screening will be shared with parents only when there 
is compelling reason to do so. 
 
g) Specimen Banking 
Upon enrollment each participant will receive a participation identification code. This 
code will be utilized to label all blood samples collected by the MSSM CRU. The 
research staff and the CRU staff will have access to the personal identification code. 
A participant contact log will be established in the form of an electronic record. This 
log will link the participant’s name, date of birth, guardian, and contact information 
with the participant identification code. This document will be password protected on 
a shared hard drive. Only the participant identification code will be utilized to 
establish participant records in the database. Access to these contact logs will be 
reserved for the coordinators assigned to this project and the P.I. 
 
The blood samples will be collected and stored at 4 degrees in a refrigerator and 
banked in locked cabinets until processed for DNA extraction. After the extraction all 
DNA samples will be stored in locked – 80 degree freezer. Numbered DNA 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
10 
Revised  9/2/14 
specimens will be shipped via UPS, packaged in dry-ice, to the attention of Ed Cook 
at the University of Chicago, Illinois for further analysis. Once there, the samples are 
given an internal lab identification number. The data that are generated will be sent 
to Mount Sinai under the Cook lab’s ID number, which will then be reverted to the 
original participant ID number. Thus the data will not be identifiable. 
Patient preferences indicated on the consent form will guide whether samples will be 
stored for future use, whether other researchers at Mount Sinai or from other 
institutions may request access to the samples, and whether the samples may be 
analyzed for the purposes related to,  or unrelated to the study. Requests from other 
researchers for analysis of the specimens will be considered by the PI, and must 
receive IRB approval before consideration.    
To ensure that adequate provisions are in place for obtaining consent from 
participants, we will re-consent subjects that turn 18 while enrolled in the 
study. After a failed good faith effort to contact the child, samples will be de-
linked.  
 
To ensure that adequate provisions are in place to safeguard the 
confidentiality of data and the privacy of subjects, specimens and/or data that 
is collected will not be used for dbGAP studies. 
h) Data Management and Confidentiality 
Participants’ names, dates of birth, and other identifying information will be   
collected and stored with the source documents.  The source documents will be 
stored and locked in filing cabinets in the locked research coordinator offices at 19 
East 98th Street.  Information (e.g., rating scales, diagnostic interviews) from the 
clinical assessments performed as part of the study will also be stored in the source 
documents.  
A participant contact log will be established in the form of an electronic record. This 
log will link the participant’s name, date of birth, guardian, and contact information 
with the participant identification code. Access to these contact logs will be reserved 
for the coordinator assigned to this project and the P.I.s. 
Information from the source documents pertinent to the research (e.g., age, 
diagnosis, results of rating scales and fMRI scans) will be entered into and stored in  
electronic databases (fMRI data is stored separately from clinical data). These 
databases will not contain identifying information (no names, social security 
numbers, or addresses) and will be indexed by a research code.   
Study office computers are connected to the internet through the MSSM network 
server and the PIs, Co-Is, and research coordinators, as well as data manager at 
MSSM have access via a password. By “MSSM Network Server” the investigator 
means a folder on the network server that has appropriate levels of protection, is 
behind the firewall and is backed up and maintained by the IT department, and is 
accessible only to authorized members of the research team. Backup files and files 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
11 
Revised  9/2/14 
to be otherwise disseminated use appropriate encryption per these guidelines 
established by Sinai IT: “ If use of a cloud service is absolutely required, the data 
must be encrypted before it is sent up the cloud service (encrypted PDF, 
Truecrypt/McAfee encrypted files)." 
Mount Sinai standards require that we retain data for a minimum of 6 years 
after the date of publication of a manuscript. Data may be kept longer in the 
event of protocol modifications. 
In constructing the combined data set, participant confidentiality will be 
protected by the use of de-identified data. 
i) Provisions to Monitor the Data to Ensure the Safety of subjects 
A DSMB will be put in place to review the conduct and safety considerations of the 
trial. The committee for the clinical trial will consist of clinical researchers who are not 
directly involved in this project and who have no stake in the outcome of the study. 
Two members of the DSMB will be psychiatrists who have extensive experience with 
ADHD clinical trials: Dr. Floyd Sallee and Dr. Chris Kratochvil. 
 
Dr. Sallee is an experienced pediatric psychopharmacologist with board certification 
in Child Psychiatry and Clinical Pharmacology. He received his M.D. from Southern 
Illinois University and his Ph.D. in Pharmacology from University of Pittsburgh. He 
has received funding as Principal Investigator from both the NIMH and NICHD for 
research in Attention Deficit Hyperactivity Disorder, including the study of anti 
psychotic pharmacotherapy for ADHD. Dr. Sallee has been mentor and co-mentor on 
several NIH-funded career development awards. He is currently Professor of 
Psychiatry at University of Cincinnati. 
 
Dr. Kratochvil is an experienced Child and Adolescent Psychiatrist. He is currently 
Director of the Division of Child and Adolescent Psychiatry and Professor of 
Psychiatry and Pediatrics at the University of Nebraska Medical Center. He is on the 
National Board of Directors for the American Academy of Child & Adolescent 
Psychiatry, Vice President of the IRB at Children’s Hospital/University of Nebraska 
Medical Center, editor of the Brown University Child & Adolescent 
Psychopharmacology Update, and sits on the American Psychiatric Association’s 
Council on Children, Adolescents, and Their Families. 
 
The DSMB will meet via conference call yearly. At an initial meeting, the DSMB 
reviewed the research protocol and plans for data and safety monitoring. Once per 
year, the DSMB will issue a report that summarizes: 
 
 
All serious and unexpected adverse events (for example, inpatient 
hospitalizations or ER weeks) or other unanticipated problems that involve 
risk to study participants or others, and whether these appeared related to the 
study-based interventions or research assessment protocols. Reports will not 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
12 
Revised  9/2/14 
specifically disclose the treatment arm of the study unless this disclosure is 
required for safety reasons. Note that any serious adverse event (SAE) will 
be reported to the local IRBs and to the DSMB within a 24 hours according to 
standard regulations. 
 
The committee’s judgments as to whether participants’ safety, privacy, and 
confidentiality have been consistently assured by the investigators 
 
The committee’s review of the study’s progress toward recruitment goals and 
participant retention/attrition rates 
 
Its review of new scientific literature pertinent to the safety of participants or 
the ethics of research participation (for example, new therapeutic or imaging 
developments) 
 
Its recommendations as to whether risk/benefit ratios have changed to the 
extent that the trial should be modified or discontinued. Specific 
recommendations for protocol modifications will be elaborated, with the 
accompanying rationale for each. 
 
These DSMB reports will be filed with the PIs, who will file them immediately 
with the IRB. The annual reports will also be filed with the NIH Project Officer 
and the NIH Office for Human Research Protections (OHRP). The reports will 
enumerate the dates that the committee met and its explicit procedures for 
monitoring participants’ safety and confidentiality, and data integrity during 
the reporting interval. 
 
There will be regular, ongoing communication between the PIs, IRB, and the 
DSMB. The PIs will take responsibility for reporting any serious and 
unexpected adverse events in a timely fashion directly to the DSMB. The PIs 
will also report serious and unexpected adverse events or other unanticipated 
study problems to the IRB. Actions taken by IRB in response to adverse 
event reports will be immediately reported to the DSMB and the NIMH Project 
Officer and OHRP office.  
 
The Mount Sinai IRB (FWA Assurance Number 0005656) will review all 
required documentation (initial and annual renewal applications, recruitment 
materials, adverse event reports, etc) for the Mount Sinai site in this project. 
 
j) Withdrawal of Subjects 
Subjects are permitted to stop their child’s participation in this research study 
at any time without any penalty or without negative affect to their child’s ability 
to receive medical care at Mount Sinai or to receive any benefits to which 
they are otherwise entitled. The PIs may also withdraw a participant from the 
study. 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
13 
Revised  9/2/14 
PI may withdraw participants from the study due to non-compliance, poor 
tolerability/adverse event, or other circumstances in which the PI believes 
continued participation would be unethical or detrimental to the child, the 
family, or to the integrity of the study. 
For the combined data set, participants have already consented to having us 
use their de-identified data. 
 
6) Risks to Subjects 
There is some physical risk to participation in the study, since children and 
adolescents will receive treatment with MPH or ATX. Although the experience of at 
least some side effects may occur, side effects are usually mild and subside after 
initiation. 
 
Common side effects of stimulant medications include: insomnia, loss of 
appetite, irritability, headache, occasional dysphoria, and tics.  
 
Common side effects of ATX include sedation, abdominal pain, loss of 
appetite, and nausea.  
 
Other more serious adverse effects can sometimes be seen.  
 
In addition, there are also risks and discomfort associated with venipunctures.  
 
Additional risks are related to confidentiality of personal information. Every effort is 
made to protect confidentiality. 
 
There are very few potential risks to participation in the fMRI scans. A small 
proportion of participants (about 3%) have difficulty tolerating the procedure because 
of claustrophobia. If a participant becomes upset by the procedure, the study will be 
terminated. There is no evidence that MRI is in any way harmful or has adverse 
effects. The Food and Drug Administration (FDA) has set recommendations for 
exposure in MRI studies and this study satisfies those criteria. Some participants find 
the loudness of the oscillating gradients during image acquisition to be discomforting, 
but the noise level is below FDA guidelines of 140 dB peak referenced to 20 
micropascals. In addition subjects are provided with ear plugs and headphones to 
reduce the noise. 
 
To manage side effects and adverse events:  
 
 
The treatment visit window can be shortened to as little as three days if 
there is non-response at any dose of either medication or placebo 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
14 
Revised  9/2/14 
 
We will employ a version of the MTA (Multimodal Treatment Study of 
Children with ADHD) ASAP (i.e., Adjunct Services, Attrition Prevention) 
manual to manage crisis situations. The ASAP manual lays out a 
procedure for assessing crisis situations, and allows for a pre-determined 
number of non-directive, supportive counseling sessions to help patients 
and families respond to crises. 
 
We will offer open treatment after completion of the randomized trial, 
beginning with study drug but extending to the use of any treatment 
approach that seems indicated  
 
We will encourage subjects to discontinue the trial if it is not in their best 
interest to remain as participants.  
 
 
There are no risks involved to participants in combining these data sets. 
 
7) Provisions for Research Related Injury 
If a subject experiences a research related injury they will be asked to 
contact the Principal Investigators immediately. During the consent 
process, the guardian will be told medical care will be provided in cases 
where there is a research related injury. Generally, this medical care will 
be billed to the participant or the participant’s health care insurance. In 
some cases, the costs of this care may be paid by someone else 
8) Potential Benefits to Subjects 
Participants will receive a comprehensive evaluation for ADHD and other disruptive 
behavior disorders, and will also be assessed for frequently occurring comorbid 
disorders. Participants will also receive a carefully titrated medication trial utilizing 
one of two commonly prescribed medications (OROS MPH or ATX), at no cost. 
Families may receive additional information about their child’s health status from the 
physical examination or urine toxicology test performed as part of the study. The 
youth may benefit from the examinations and evaluations in this study, although they 
are not specifically administered for benefit, but as a precaution. 
 
OROS MPH and ATX have both been shown to be effective in the treatment of 
ADHD, and are approved by the FDA for this purpose. Since the youth treated with 
these medications will have ADHD, they are expected to show improvement in these 
symptoms. As response is not 100%, not all children and adolescents with ADHD will 
improve during the randomized clinical trial. However, there is an open treatment 
period following the trial which will provide medication stabilization prior to referral to 
a community provider. 
 
Parents and youth are asked to rate their satisfaction with the study medication as 
part of the trial, and have an opportunity to continue with the medication after the 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
15 
Revised  9/2/14 
trial. In addition, non-responders or non-toleraters of one treatment will have an 
opportunity for treatment with other agents during the open treatment period. 
 
Information obtained from this study may benefit patients in the future. Thus, these 
data are potentially of vital importance to patients, families and clinicians in treatment 
selection, and identifying the neurobiological underpinnings of successful treatment. 
 
There is neither potential benefit or harm to participants in combining the data sets, but 
there is potential benefit to  the field and to others with the ADHD diagnosis from 
conducting the additional well-powered analyses proposed here. 
 
9) Provisions to Protect the Privacy Interests of Subjects 
Steps to be taken to protect participant privacy interests include conducting all   
study procedures in private offices with the research staff. Participants will be asked 
to provide a preferred method of contact e.g. phone or email. Information that is 
deemed sensitive or private will only be disclosed to the participant,members of the 
study team, or to appropriate sources inside the Mount Sinai Health System for 
purposes of arranging clinical referrals and helping subjects obtain clinical care.  
10) 
Economic Impact on Subjects 
Subjects may incur financial burden related for travel expenses to attend study visits 
and for time lost from work. 
There is no additional burden or financial impact of combining the data sets. 
 
 
11) 
Payment to Subjects 
This research project is funded by the NIH. Drs. Jeffrey Newcorn (Co-PI) and Kurt 
Schulz (Co-PI) will be responsible for the budget management of the grant. Parents 
of participants will be compensated $25 for each weekly medication visits for up to 8 
visits (total of up to $200 per child with ADHD) and $50 at each scan visit to help 
cover cost of transportation and inconvenience for weekly visits. The participant will 
receive $50.00 for each scan visit (total of $100 per scan/ $200 per family). In 
addition, parents will receive $100 for their time and effort spent during the 
screening process (total of $100 per family). Maximum reimbursement for a family 
of a child with ADHD is $500. Maximum reimbursement for a family of a healthy 
child without ADHD is $300. 
There is no additional payment to subjects for inclusion in the combined data set. 
12) 
Consent Process 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
16 
Revised  9/2/14 
Consent forms will be sent to the parents of potential participants prior to the study. 
This allows time for the parent to read through the consent carefully before the initial 
screening evaluation appointment. Consent will be obtained on the day of the 
evaluation in a private medical office (room 5-E) in 19 East 98th Street, or similarly 
private offices at a referring site (ex., the OPD clinic at St. Lukes).  When participants 
arrive at MSSM for the evaluation, the principal investigator (PI) or one of the 
delegates will give a thorough description of the project to them, and will answer any 
questions they might have about the study.  The SOP HRP-090 Informed Consent 
Process for Research will be followed and provide guidance regarding who may sign 
consent. In keeping with policy 3.4.2, we will obtain consent from both parents when 
both parents are reasonably available. It is our experience that both parents are 
rarely available to consent, due to divorce, work schedules, or other circumstances. 
Therefore, we expect the majority of participants to have consents signed by one 
parent or legally authorized representatives (LAR). We will accept consent from 
biological and adoptive parents, and LAR’s (i.e., grandparents who are legal 
guardians). Our guidance comes from the IRB HRP-013 form, which defines ‘“legally 
authorized representative” as an individual or judicial or other body authorized under 
applicable law to consent on behalf of a prospective subject to the subject’s 
participation in the procedure(s) involved in the research’. Additional guidance comes 
from policy 3.1.1.1 and 3.3 of the HRP-013. 
 
We will share results of positive pregnancy and drug tests with parents when there is  
compelling social, medical or other need to share with the parents. This will be made 
explicit at assent, and will be documented.  
 
To assist individuals who fail the prescreening interview in finding appropriate care, 
we will offer to share their contact information and evaluation status with our referral 
sources. We will only share this information for clinical referral purposes.  
 
There is no additional consent involved in combining the data sets.  
 
 
13) 
Process to Document Consent in Writing 
After a thorough description of the research including the risks and benefits and the 
alternatives to participation, parents of the participants will be asked to sign the 
consent form. The witness will sign and date the “Certification of Assent of Minor” to 
document that the child freely assented to participate. 
14) 
Vulnerable Populations 
Include 
Exclude 
Vulnerable Population Type 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
17 
Revised  9/2/14 
 
x 
Adults unable to consent 
x 
 
Individuals who are not yet adults (e.g. infants, children, 
teenagers) 
 
x 
Wards of the State (e.g. foster children) 
 
x 
Pregnant women 
 
x 
Prisoners 
 
15) 
Multi-Site Human Research (Coordinating Center) 
NA 
16) 
Community-Based Participatory Research 
NA 
17) 
Sharing of Results with Subjects 
With appropriate authorization, parents may access results that are relevant to their 
children’s ongoing clinical care. Results of assessments that are done only for study 
purposes (e.g. fMRI scan, genetic analysis, and behavioral data), and/or that are 
not useful for ongoing clinical care are not shared with the patients. Upon 
completion of the protocol, at the discretion of the PIs, participants may also receive 
either a letter to provide to their follow-up care provider or the patient may authorize 
the study team to provide information about the participant’s treatment directly to 
the care provider.  
 
 
 
18) 
IRB Review History 
This project was approved on 7/3/12 and was re-approved on 8/10/12 after receipt of 
funding. This study has been approved at annual reviews since its inception. It is 
currently approved until 4/30/2017 
 
19) 
Control of Drugs, Biologics, or Devices 
Drug is purchased through the IDS and dispensed by the Mount Sinai research 
pharmacy. For drug accountability, bottles will be returned to the study team at each 


 
Protocol Title: 
Imaging Stimulant and Non-Stimulant Treatments for 
ADHD: A Network-Based Approach 
Principal Investigator 
Name/Contact Info:  
Jeffrey Newcorn, MD 
212-659-8775 
Primary Contact 
Name/Contact Info 
Beth Krone, PhD 
212-241-8012 
Date Revised: 
5/6/2019 
Study Number: 
GCO 11-0161,  
 
18 
Revised  9/2/14 
participant visit. In the event that they cannot be returned immediately to the 
pharmacy, the returned drug will be held in a locked safe that meets and exceeds 
DEA standards for storage of a Class II drug. This safe is located in the Mount Sinai 
School of Medicine and belongs to the PIs.  
 
 
 

SAP_001.pdf: 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Imaging Stimulant and Non-Stimulant Treatments fro ADHD: A Network-Based Approach  
PI: Jeffrey Newcorn  
NCT01678209  
Statistical Analysis Plan 
Document Date: 5/22/2019 
 
 


5.5.2. SPECIFIC AIMS 
Despite a general convergence of findings from neuroimaging studies implicating several key brain regions in the 
pathophysiology of attention deficit hyperactivity disorder (ADHD) and data regarding the acute neurobiological 
effects of stimulant medications, the mechanisms by which ADHD treatments produce clinical improvement are 
not well understood. We recently completed an NIMH-funded R01 supplement comparing the mechanisms of 
action of methylphenidate (MPH) and atomoxetine (ATX) using functional magnetic resonance imaging (fMRI) over 
7 weeks of treatment. Findings indicate that the two medications produce clinical improvement through common 
and unique mechanisms in regions of the anti-correlated ‘task-positive’ fronto-striatal and ‘task-negative’ cingulate-
precuneus networks.3,4 Symptomatic improvement with both medications was associated with reduced activation 
in motor cortex, but there were divergent effects in inferior frontal cortex (IFG), anterior cingulate cortex (ACC), and 
posterior cingulate cortex (PCC) – with increased activation for ATX and decreased activation for MPH. Based on 
these findings, we have developed a model which posits that ATX primarily works by increasing activation (i.e., 
signal) in the ‘task-positive’ fronto-striatal network, with resultant increase in PCC activity to maintain competitive 
balance between the networks, while MPH primarily produces improvement by decreasing activity (i.e., noise) in 
the ‘task-negative’ default network (i.e., PCC), with resultant decreases in activation (i.e., increased efficiency) in 
the fronto-striatal network. We are very excited by these findings, which we believe offer a window into the 
neurophysiological basis of differential response to stimulant and non-stimulant treatments. However, to more 
thoroughly understand the mechanisms through which these treatments exert their effects requires in-depth 
investigation of neural networks (rather than single brain regions) before and after treatment, and consideration of 
whether clinical improvement is achieved via normalization of pathophysiology or other compensatory changes. 
We are therefore proposing a network-based study of the effects of MPH and ATX treatment in a large sample of 
ADHD youth scanned with fMRI before and after treatment (to determine comparative treatment effects on brain 
function), and a group-matched sample of healthy controls (to establish ‘normal’ connectivity). We will investigate 
three specific aims:  
Aim 1: Delineate functional impairments in ‘task-positive’ and ‘task-negative’ neural networks in youth with 
ADHD. Emergent findings5,6 7-10 implicate functional disconnections within and between the ‘task-positive’ (i.e., IFG, 
caudate nucleus, ACC) and ‘task-negative’ (i.e., PCC, precuneus, medial prefrontal cortex [MPFC]) networks in 
the pathophysiology of ADHD. We predict that impaired response inhibition in youth with ADHD versus normal 
controls will be associated with reduced functional connectivity (i.e., co-activation) between: 
a) ‘Task-positive’ regions: IFG, caudate, ACC, and related structures (e.g., frontal operculum, dorsolateral 
prefrontal cortex [DLPFC], motor cortex); 
b) ‘Task-negative’ regions: PCC, precuneus, MPFC and related areas (e.g., posterior inferior parietal lobule); 
c) ‘Task-positive’ regions (i.e., ACC, IFG, caudate) and ‘task-negative’ regions (i.e., PCC, precuneus, MPFC). 
Aim 2: Determine the common brain mechanisms which underlie successful treatment with stimulant and 
non-stimulant medications. Our previous findings and pilot data suggest that successful treatment involves 
certain common features, including both ‘normalization’ of pathophysiology and compensatory changes. We 
hypothesize that symptomatic improvement for both ATX and MPH will be related to: 
a) Normalization of reduced IFG connectivity with caudate nucleus and reduced IFG inhibition of motor cortex, 
which may reflect the suppression of pre-potent responses; 
b) Compensatory increases in the functional connectivity of ACC with PCC and IFG with precuneus – ‘task-positive’ 
and ‘task-negative’ regions that are typically anti-correlated. 
Aim 3: Determine the specific mechanisms by which MPH and ATX produce clinical improvement. Our 
previous findings and pilot data suggest that MPH and ATX produce clinical benefits via distinct mechanisms in 
‘task-positive’ and ‘task-negative’ networks. We predict that improvement will be differentially associated with: 
a) Normalization of reduced ACC-DLPFC and IFG-frontal operculum connectivity for ATX, and PCC-precuneus 
and PCC-MPFC connectivity for MPH; 
b) Compensatory increases in functional connectivity between IFG and MPFC for ATX and between ACC and 
MPFC for MPH – ‘task-positive’ and ‘task-negative’ regions that are typically anti-correlated. 
The proposed investigations are both innovative and unique; we know of no other data comparing mechanisms 
of stimulant and non-stimulant medications. Our research has yielded important findings regarding common and 
distinct effects of MPH and ATX, which we have used to develop a model positing divergent mechanisms in 
‘task-positive’ and ‘task negative’ networks. Validation of this model would constitute important progress in 
delineating the neurobiological basis of differential response to stimulant and non-stimulant medications, and 
offer a scientific basis on which to develop research examining individualized approaches to treatment. 
 


C.5.     DATA PREPARATION 
C.5.1.  Behavioral variables.  
C.5.1.1. Symptomatic improvement. Percent change in the ADHD-RS-IV total score over treatment will serve as 
the measure of clinical improvement in the multiple linear regression. Percent change on the ADHDRS-IV is 
calculated individually for each subject by subtracting the post-treatment score from the pre-treatment score, 
dividing the difference by the pre-treatment score, and multiplying the quotient by 100. The ADHD-RS-IV change 
scores for the 36 subjects described in the Preliminary Studies section were normally distributed, with a mean (SD) 
of 56 (28). If the scores are not normally distributed or there are visible outliers, log transformations will be 
considered or nonparametric procedures will be utilized. 
C.5.1.2. Task performance. The effects of treatment on go/no-go performance will be tested to inform the 
interpretation of the fMRI results. The percentage of commission errors on no-go trials (false alarms) will serve as 
the measure of response inhibition. Differences in go/no-go task performance between youth with and without 
ADHD will be tested with a linear 2-level mixed models, in which Group (MPH vs. ATX vs. control) will serve as the 
between-subjects factor and Time (baseline vs. endpoint) will be the within-subjects factor. 
C.5.2.  Functional images. Preprocessing and modeling the fMRI data replicate the MACRO supplement. 
C.5.2.1. Preprocessing of functional images. The six functional time series for the go/no-go task acquired at 
baseline and endpoint for each ADHD and control subject will be separately realigned, co-registered to the high-
resolution T2 images, co-registered to each other, normalized, and then smoothed. 
C.5.2.2.  First-level analysis: within-subject modeling of activation. We will use a within-subjects design to model 
activation in the baseline and endpoint time series for each subject individually, as a prelude to extracting PPI data. 
The relationship between the observed event-related BOLD signals and regressors that represent expected neural 
responses to events will be determined with a general linear model (GLM).87 Four regressors representing correct 
and incorrect no-go and go events will be entered in the GLM. Six motion correction parameters will also be entered 
as covariates of no interest.88 The appropriate linear contrasts will be applied to the parameter estimates for correct 
no-go events minus correct go events in the baseline scan for control subjects only (see next section) and in the 
endpoint minus baseline scans for all subjects. The endpoint minus baseline contrast maps will be used to extract 
PPI data (see next section). 
C.5.2.3. First-level analysis: within-subject modeling of psychophysiological interaction (PPI). PPI is a regression-
based method of functional connectivity that tests for differences in the regression slope of activation between 
brain regions due to differential responses in one region (seed) to different experimental contexts.69,70 An initial 
one-sample t-test will identify regions activated/deactivated for response inhibition at baseline in the control 
subjects to determine ‘normal’ levels of activity and connectivity. PPI will be calculated using the methods described 
in Fan et al.68 and Schulz et al.89 Briefly, seed volumes of interest (VOI) will be extracted for all subjects from 8-
mm radius spheres centered on the maximal local peak in the regions identified by the t-test. The appropriate linear 
contrasts will be applied to the parameter estimates for the PPI regressor in the baseline and endpoint scans, 
resulting in ‘baseline connectivity’ and ‘endpoint connectivity’ contrasts maps for all subjects. In addition, linear 
contrasts will be applied to parameter estimates for the PPI regressor in the post-treatment minus baseline scans 
for ADHD subjects only (‘post–baseline connectivity’). 
C.6. STATISTICAL ANALYSIS 
C.6.1. Second-level group analysis. We have adopted a two step approach to hypothesis testing. We will first 
use analyses of covariance (ANCOVA) to test for connectivity changes over treatment and then use multiple linear 
regression to test the association of these changes with clinical improvement. Statistical significance will be set at 
a height (intensity) threshold of p < 0.01 and an extent (cluster) threshold of 100 contiguous voxels to correct for 
multiple comparisons at p < 0.01.90 
C.6.1.1. Analysis of covariance (ANCOVA). The ‘baseline connectivity’ and ‘endpoint connectivity’ contrast maps 
for all subjects will be entered into a random-effects GLM, in which Group (ATX vs. MPH vs. control) will serve as 
the between-subjects factor and Time (baseline vs. endpoint) will be the within-subjects factor. Age of subjects will 
be entered as a covariate to remove any developmental effects. The concepts of ‘normalization’ and 
‘compensation’ in Aims 2 and 3 are defined as Group × Time interactions that indicate differences in connectivity 
at baseline but not endpoint and at endpoint but not baseline, respectively (see Fig. 3).  
C.6.1.2. Multiple linear regression. The ‘post-baseline connectivity’ contrast maps for ADHD subjects only will be 
entered into a random-effects GLM with three regressors: (i) Medication (MPH vs. ATX); (ii) ADHD-RS-IV change 
score; and (iii) an interaction predictor, which is the product of the Medication variable with the ADHD-RS-IV change 


score. Age of subjects will initially be entered as a covariate; secondary analyses will include age as a regressor 
crossed with both Medication and ADHD-RS-IV change score to explore potential development effects. A mask 
will restrict the analyses to regions that showed significant Group × Time interactions in the ANCOVA. The ADHD-
RS-IV change score and the interaction predictor identify connectivity changes that are associated with 
improvement across the whole sample (i.e., common effects) and differentially in the MPH and ATX groups (i.e., 
unique effects). The medication regressor is of no interest since it is not linked to improvement. The interaction 
predictor involves a between-group contrast that subtracts-out changes shared by the ATX and MPH groups – 
including practice, expectation, and other non-specific factors. 
C.6.2. Hypothesis testing.  
C.6.2.1. Hypotheses 1a-c: Youth with ADHD have reduced connectivity between and within ‘task-positive’ and 
‘task-negative’ networks compared to controls would be confirmed by significant Group × Time interactions in the 
ANCOVA indicating that the two ADHD groups have lower connectivity compared to controls at baseline: a) 
between IFG and caudate, motor cortex, and frontal operculum and between ACC and DLPFC (within the ‘task-
positive’ network); b) between PCC and MPFC and precuneus (within the ‘task-negative’ network); and c) between 
ACC and PCC and MPFC, and between IFG and precuneus and MPFC (between the two networks). 
C.6.2.2. Hypothesis 2a: Symptomatic improvement for both ATX and MPH is associated with normalization of 
reduced connectivity within the ‘task-positive’ network would be confirmed by finding: i) significant Group×Time 
interactions in the ANCOVA indicating lower IFG-caudate and IFG-motor cortex connectivity in both the ATX and 
MPH groups compared to controls at baseline but not endpoint; and ii) positive associations between the ADHD-
RS-IV change score and IFG-caudate and IFG-motor cortex connectivity in the regression. 
C.6.2.3. Hypothesis 2b: Symptomatic improvement for both ATX and MPH is associated with compensatory 
increases in connectivity between ‘task-positive’ and ‘task-negative’ networks would be confirmed by findings of 
both: i) significant Group × Time interactions in the ANCOVA indicating lower ACC-PCC and IFG-precuneus 
connectivity in both the ATX and MPH groups compared to controls at endpoint but not baseline; and ii) positive 
associations between the ADHD-RS-IV change score and ACC-PCC and IFG-precuneus connectivity in the 
regression. These results would reflect increased connectivity between anti-correlated networks.3,4 
C.6.2.4. Hypothesis 3a: Symptomatic improvement is associated with normalization of reduced ‘task-positive’ 
network connectivity for ATX and reduced ‘task-negative’ network connectivity for MPH would be confirmed by 
findings of: i) significant Group × Time interactions in the ANCOVA indicating lower ACC-DLPFC and IFG-frontal 
operculum connectivity for ATX-treated subjects compared to MPH-treated subjects and controls at baseline, but 
not endpoint; ii) significant Group × Time interactions in the ANCOVA indicating lower PCC-precuneus and PCC-
MPFC connectivity for MPH compared to ATX and controls at baseline but not endpoint; and iii) positive 
associations between the interaction predictor and IFG-caudate and IFG-motor cortex connectivity for ATX and 
PCC-precuneus and PCC-MPFC connectivity for MPH in the multiple regression. 
C.6.2.5. Hypothesis 3b: Symptomatic improvement is associated with compensatory increases in connectivity 
between ‘task-positive’ and ‘task-negative’ networks would be confirmed by findings of: i) significant Group × Time 
interactions in the ANCOVA demonstrating lower IFG-MPFC for ATX compared to MPH and controls at endpoint 
but not baseline; ii) significant Group × Time interactions in the ANCOVA indicating lower ACC-MPFC for MPH 
compared to ATX and controls at endpoint but not baseline; and iii) associations between the interaction predictor 
and IFG-MPFC connectivity for ATX and ACC-MPFC connectivity for MPH in the multiple regression. These results 
would reflect increased connectivity between typically anti-correlated networks.3,4 
C.6.2.6. Exploratory Aim 1: Establish direct causal models of the therapeutic actions of ATX and MPH. The PPI 
results will be used to inform direct causal modeling (DCM) of the directionality or effective connectivity of the 
therapeutic actions of ATX and MPH on interactions between and within the ‘task-positive’ and ‘task-negative’ 
networks, as described in Fan et al.68 and Wang et al.67  
C.6.2.7. Exploratory Aim 2: Changes in connectivity associated with improvement on neurocognitive measures of 
treatment outcome. Percent change in the Digit Span, Finger Windows and Attention Network (ANT) Tests 
(neuropsychological outcome measures of attention and executive function) will be used in the two step analytic 
model described above to identify changes in connectivity associated with various cognitive outcomes.